

Pharmacokinetics of 5-aminolevulinic acid-induced protoporphyrin IX in skin and blood

K. Rick ^{a,1}, R. Sroka ^a, H. Stepp ^a, M. Kriegmair ^b, R.M. Huber ^c, K. Jacob ^d, R. Baumgartner ^{a,*}

^a Laser-Research Laboratory at the Department of Urology, University of Munich, Munich, Germany

^b Department of Urology, University of Munich, Munich, Germany

^c Department of Medicine, University of Munich, Munich, Germany

^d Institute of Clinical Chemistry, University of Munich, Munich, Germany

Received 10 March 1997; accepted 11 July 1997

Abstract

The fluorescence and photosensitivity of endogenously synthesized protoporphyrin IX (PPIX) is increasingly used for the diagnosis and treatment of malignant and certain non-malignant diseases. A selective accumulation of PPIX can be induced by application of 5-aminolevulinic acid (5-ALA), which is a precursor of PPIX in the cellular biosynthetic pathway of heme.

The purpose of this study was to monitor the *in vivo* accumulation of PPIX in different locations of the skin after oral ingestion and to determine the pharmacokinetics of 5-ALA and PPIX in human blood plasma for various routes of application. At the same time we wanted to achieve an optimal treatment scheme but also study possible side-effects of 5-ALA administration.

After oral application of 5-ALA in a concentration of 40 mg kg⁻¹ body weight, the fluorescence intensities of PPIX in the skin showed maxima between 6.5 and 9.8 h depending on the location and decreased to values lower than 5% related to the maximum after a mean time of about 40 h. The measured absolute intensities of PPIX fluorescence varied strongly between different patients and different locations on one patient. In the plasma of blood samples, PPIX could be detected via its fluorescence for all studied routes of application with the exception of the ointment, where PPIX levels were below the detection limit of 1 µg l⁻¹. The highest mean concentration of 742 µg l⁻¹ PPIX in the plasma was measured 6.7 h after oral application. For inhalation of 5-ALA, a mean maximum concentration of 12 µg l⁻¹ could be detected 4.1 h after application, for intravesical instillation, the mean maximum concentration was found to be 1 µg l⁻¹ 2.9 h after application. The kinetics of 5-ALA in the plasma peaked much earlier with a maximum concentration of 32 mg l⁻¹ about 30 min. after oral administration. The 5-ALA levels did not exceed normal reference values after topical application.

The results of our experiments suggest that for a systemic application of 5-ALA side-effects in sensitive patients cannot be excluded.
© 1997 Elsevier Science S.A.

Keywords: Porphyrins; Fluorescence; Photodynamic diagnosis; Photodynamic therapy; Side-effects

1. Introduction

Usually, photodynamic diagnosis and therapy require the administration of exogenous photosensitizers. Besides synthetic photosensitizers like Photofrin[®], there are several potential endogenous sensitizers synthesized during the biosynthesis of heme. Under physiological conditions, a feedback loop controls the metabolic steps of heme biosynthesis and excludes an accumulation of any photosensitizing con-

centrations of the involved intermediates [1]. The intracellular concentration of free heme in the liver inhibits the synthesis of 5-aminolevulinic acid (5-ALA) and thus all following metabolites as a rate-limiting factor [2]. Enzymatic defects associated with the metabolic steps result in abnormal quantities of the corresponding porphyrins in the biosynthetic pathway. The clinical manifestation of the resulting cutaneous porphyrias include acute or chronic photosensitization of the skin [1]. Investigations of Berlin et al. in 1956 [3] showed that the administration of an excess of exogenous 5-ALA bypasses the cellular feedback control mechanism even in normal organisms. The resulting accumulation of protoporphyrin IX (PPIX), an immediate precursor of heme in the biosynthesis, leads to comparable

Abbreviations: PPIX, protoporphyrin IX; 5-ALA, 5-aminolevulinic acid

* Corresponding author. Laser-Forschungslabor, Urologische Klinik der Ludwig-Maximilians-Universität München, Marchioninistrasse 23, D-81377 Munich, Germany. Tel.: +49 89 70906162; Fax: +49 89 70906142; e-mail: baumgartner@life.med.uni-muenchen.de

¹ Part of thesis

symptomatic photosensitization of the skin as seen in the cutaneous porphyrias [1,4].

The quantitative expression and regulation of heme production differs from tissue to tissue. Changes in heme biosynthesis of certain malignant cells, in particular, seem to correlate with a preferential accumulation of 5-ALA induced PPIX [4]. At present, the tumorselective potential of PPIX and its clinical value for photodynamic diagnosis and treatment of neoplastic lesions are part of extensive investigations [5–12]. Clinical experience has been reported for systemic and different topical routes of 5-ALA application [13–18].

Considering both the many different application schemes as well as the possible systemic side-effects of the 5-ALA administration, a thorough knowledge of the time course and the distribution of 5-ALA and the induced PPIX are of significant importance. Moreover, the pharmacokinetics of 5-ALA and its metabolites *in vitro* and *in vivo* provide the basis for a better understanding of the involved mechanisms. The systemic load of patients with 5-ALA and PPIX at different times after application can be evaluated analytically by means of a biochemical assay of the blood samples from the patients. In addition, the skin photosensitization due to PPIX after oral ingestion of 5-ALA can be estimated by measuring the fluorescence intensity of PPIX in the skin. The purpose of this study was to monitor PPIX on different locations of the skin after oral ingestion and to determine kinetics of 5-ALA and PPIX in human blood plasma for various routes of application.

2. Materials and methods

2.1. PPIX fluorescence kinetics in the skin

11 patients (mean age 70 a, SD 6.2 a, range 62 to 79 a) proposed for photodynamic diagnosis or treatment were

included in this investigation. After informed consent had been obtained, all patients received 40 mg kg⁻¹ body weight 5-ALA dissolved in mineral water *per os* in a single bolus. All patients were kept in a darkened room for 24 h after 5-ALA ingestion.

For a reproducible recording of PPIX fluorescence kinetics at a constant distance to the skin, a handheld detection device was designed to allow for a homogenous illumination of the probing location by the light of a modified Xenon short arc lamp (D-Light, Storz, Tuttlingen, Germany) (Fig. 1).

To ensure an efficient excitation of PPIX within its absorption band centered at $\lambda = 408$ nm, the light source was equipped with a bandpass filter system transmitting blue-violet light in the spectral range of $\lambda = 375$ to 440 nm. The total irradiation of the tissue was limited to 4 mJ cm⁻² for each measurement and location in order to prevent photobleaching effects [19].

As shown in Fig. 1, the remitted fluorescence light was collected by a fused silica fiber (HCN600, core diameter 600 μ m) and analyzed spectroscopically by means of an intensified optical multichannel analyzer (O-SMA 3, SI Spectroscopy Instruments, Gilching, Germany). A sufficient blocking of the excitation light was obtained by a combination of two longpass filters (KV 450, GG 455, Schott, Mainz, Germany) mounted behind the entrance slit of the monochromator. Emission spectra were recorded in the spectral range between $\lambda = 450$ and 750 nm and corrected according to the background and the wavelength sensitivity of the system.

To separate the specific fluorescence of PPIX from the autofluorescence of the skin, the ratio of the integral autofluorescence intensities at $\lambda = 635 \pm 5$ nm and $\lambda = 590 \pm 5$ nm was calculated for all spectra recorded from the skin prior to the application of 5-ALA and free of any porphyrin peaks. If this ratio is applied, the contribution of the autofluorescence to the integral fluorescence intensity at $\lambda = 635 \pm 5$ nm can




Fig. 1. Experimental setup used for the measurement of PPIX fluorescence kinetics in the skin.

Table 1
Doses and number of patients for different routes of application

Delivery	Dose	n
Oral	40 mg/kg body weight	12
Inhalation	500 mg (10%)	5
Intravesical instillation	1 g (2%)	5
Ointment	200 mg (10%)	1

be determined and then subtracted for each set of spectra. Subsequently, the resulting specific fluorescence intensities for PPIX at $\lambda = 635 \pm 5$ nm were plotted as a function of time.

2.2. Pharmacokinetics of 5-ALA and PPIX in blood plasma

Pharmacokinetic measurements in human blood plasma were performed for different routes of 5-ALA application. The applied doses for clinical 5-ALA assisted photodynamic diagnosis or therapy are listed in Table 1.

The application procedure for oral ingestion of 5-ALA is similar to the one described in the context of the skin measurements. For inhalation of 5-ALA, a concentration of 10% (500 mg 5-ALA in 5 ml isotonic saline) was applied 30 to 40 min. by means of a medical nebulizer (Inhalierboy, Pari, Starnberg, Germany). Intravesical instillation of the 5-ALA solution (1 g 5-ALA in 50 ml 1 M NaHCO_3) was performed via a catheter and incubated for a period of 2 to 4 h. For topical application as an ointment, a water-in-oil based cream containing 10% of 5-ALA (200 mg 5-ALA in 2 g cream) was applied and covered for 6 h with an occlusion pad.

Venous blood samples of all patients were collected immediately before and at various times between one and 48 hours after 5-ALA application. Blood was collected into EDTA tubes and protected from light during the whole preparation procedure. The separated plasma was stored at a temperature below 20 °C until analyzed.

The amount of 5-ALA in the plasma of two patients was determined by an HPLC method using fluorescence detection as described by Tomokuni et al. [20].

PPIX was extracted from the plasma using a mixture of acetonitrile and ethanol (1:8) as a solvent. Plasma and solvent in the ratio of 1:9 were mixed for one minute by a sonifier (Sonifier 250, Branson, Danbury, CT, USA). After one hour the mixture was centrifuged in an ultra centrifuge (Cryofuge 800, Heraeus, Hanau, Germany) for ten minutes at 5700g. Fluorescence spectra of the supernatant were measured with a fluorescence spectrometer (Luminescence Spectrometer LS 50, Perkin Elmer, Überlingen, Germany) at a spectral resolution of $\Delta\lambda = \pm 2$ nm. According to the Soret band of PPIX dissolved in ethanol, emission spectra of the supernatant were measured at the excitation wavelength of 405 nm. Subsequently, excitation spectra were recorded for all peak wavelengths appearing in the emission spectra. All emission spectra were corrected as to the background of the solvents used and the recovery rate. PPIX concentrations were calculated on the basis of the PPIX fluorescence measurements

after the calibration of fluorescence intensities obtained from standard solutions of PPIX (Porphyrin Products, Logan, UT, USA). The PPIX concentrations of these standard solutions were determined via the absorbance measured at 405 nm (Diode Array Spectrophotometer 8452A, Hewlett Packard) using Beer's law, the extinction coefficient $\epsilon = 1.71 \times 10^5$ l mol⁻¹cm⁻¹ for PPIX in ethanol [21] and the molecular weight of PPIX = 562.7 g mol⁻¹. Fluorescence intensities were measured in the spectral range of $\lambda = 635 \pm 5$ nm for a series of 10 diluted solutions prepared in the range between 10 µg l⁻¹ and 10 mg l⁻¹, thus showing a linear relationship between absorption and fluorescence. By extrapolation to lower values, PPIX-concentrations of plasma samples could be determined down to 1 µg l⁻¹.

Kinetics based on the achieved values are fitted by using least squares fitting procedures [22] and rate constants according to a one-compartment model for 5-ALA and a three-compartment model for PPIX [5,6].

Spectral identification of the contributing fluorophores was achieved by comparing the resulting spectra with emission and excitation spectra recorded from standard solutions of uroporphyrin I/III, coproporphyrin I/III and protoporphyrin IX (Porphyrin Products, Logan, UT, USA) using the above mentioned combination of acetonitrile and ethanol (1:8) as a solvent. Mixtures containing uro-, copro- and protoporphyrin IX in varying ratios of concentration showed the contribution of the different porphyrins to the peak positions of the measured emission and excitation spectra.

By dissolving and extracting a known amount of PPIX in fresh and untreated human plasma the recovery rate of the procedure was found to be 72%.

3. Results

3.1. PPIX fluorescence kinetics in the skin

Fig. 2 shows fluorescence spectra (before, 7 h and 50 h after application) taken from a series of spectra recorded on




Fig. 2. Fluorescence spectra recorded on the forearm of one patient before, 7 h and 50 h after oral application of 5-ALA.




Fig. 3. PPIX fluorescence kinetics of forearm skin (same patient as in Fig. 2). Peak values at $\lambda = 635 \pm 5$ nm are corrected for autofluorescence and background.

Table 2

Mean parameters calculated from the fits of the PPIX fluorescence kinetics after oral application of 5-ALA. The left column shows the absolute mean peak times for different locations as averaged for all patients. For the second and third columns (relative), the ratios of the peak times and intensities related to the first location "back of the hand" are determined individually and averaged for the patients subsequently. Since the standard deviation (SD) was comparable for the different locations, the mean SD is calculated independently of the locations

Location	$t_{\max}$ (absolute) [h]	$t_{\max}$ (relative)	$I_{\max}$ (relative)
Back of the hand	6.5	1.0	1.0
Lip	7.9	1.3	9.4
Cheek	8.7	1.5	7.3
Forearm	9.8	1.7	1.4
SD [%]	15	10	25

a patient's forearm before and at various times between 30 min and 50 h after oral 5-ALA application.

In none of the spectra recorded from human skin, any indication for the presence of porphyrins other than PPIX could be found. The fluorescence kinetics for PPIX measured on the forearm is shown in Fig. 3 showing a peak after 7 h and a fast decrease to baseline levels within 40 h. The highest fluorescence intensities were measured for the areas of head and neck, especially the lips. It was observed that PPIX fluorescence intensities decreased towards the extremities. The lowest signals, however, were detected on the trunk. Table 2 summarizes the results of the PPIX fluorescence kinetics measured on some characteristic locations of the skin.

As seen in the right column of Table 2, the lowest mean intensity was observed at the back of the hand with the maximum intensity already 6.5 h after application. The kinetics of the lip with the highest intensities measured peaked after 7.9 h, followed by the cheek with the maximum intensity after 8.7 h and the forearm after 9.8 h. After a mean time of about 40 h after application (SD 9.3, range 24 to 60 h) the

PPIX-fluorescence intensities decreased to values lower than 5% of the maximum for all locations.

3.2. Pharmacokinetics of 5-ALA and PPIX in blood plasma

Both emission and excitation spectra of the plasma recorded after application of 5-ALA showed the typical shape and peak positions of PPIX. There was no spectral indication for the presence of other porphyrins. Fig. 4 compares some characteristic examples of the kinetics of PPIX in blood plasma for various routes of application.

Table 3 summarizes the results of the determination of PPIX in the plasma according to the fitted kinetics and averaged for all patients: For oral application, we found an average peak concentration of $742 \mu\text{g l}^{-1}$ PPIX in the blood plasma 6.7 h after application. For inhalation, an average peak concentration of only $12 \mu\text{g l}^{-1}$ was reached already 4.1 h after application. The average peak concentration for intra-vesical instillation was $1 \mu\text{g l}^{-1}$ and close to the detection limit. For topical application of 5-ALA using an ointment, no PPIX could be detected in the plasma. The average time $t_{0.05}$ at which the PPIX concentration decreased to values lower than 5% of the maximum was less than 35 hours for all routes of delivery.

In summary, the ratio of the maximum concentrations was found to be 742 (oral):12 (inhalation):1 (instillation).




Fig. 4. Comparison of the PPIX concentrations in the plasma after systemic and topical application.

Table 3

Averaged results of the fitted PPIX plasma kinetics (corresponding standard deviations in brackets). A mean maximum concentration $c_{\max}$ was reached at the mean peak time $t_{\max}$ and decreased to values lower than 5% of the maximum at $t_{0.05}$ (n.d. = not detected)

Application	$t_{\max}$ [h] (SD)	$t_{0.05}$ [h] (SD)	$c_{\max}$ [$\mu\text{g/l}$] (SD)
Oral	6.7 (0.8)	35 (4.6)	742 (87)
Inhalation	4.1 (0.8)	21 (7.8)	12 (2.9)
Instillation	2.9 (0.5)	n.d.	1 (0.8)
Ointment	n.d.	n.d.	n.d.




Fig. 5. Comparison of the PPIX skin kinetics (a.u.), PPIX (right axis) and 5-ALA (left axis) plasma kinetics after oral application.

The time course of the 5-ALA kinetics (Fig. 5) was much faster than all PPIX kinetics. A 5-ALA peak concentration of 32 mg l^{-1} was reached already 30 min. after systemic application with a return to baseline levels in less than 8 h. In contrast to these observations, the measured maximum concentrations for topical application did not exceed the detection limit of 0.1 mg l^{-1} set by the HPLC technique used in the experiments [20].

4. Discussion

4.1. PPIX fluorescence kinetics in the skin

The present study describes the *in vivo* kinetics of 5-ALA induced PPIX for various routes of application. For systemic administration (oral), the PPIX kinetics in normal skin was assessed by *in vivo* fluorometric measurements. Apart from that, we investigated time course and peak levels of both 5-ALA and PPIX in human blood plasma for systemic and various topical routes of delivery (inhalation, instillation, ointment).

All kinetics recorded from different locations of the skin showed similar time courses, although peak times and intensities seemed to depend on both location and individual variations between the patients. After oral administration of 5-ALA, the fluorescence kinetics of PPIX in normal skin reached maximum values after about 8 h followed by a decline to baseline levels after 40 h.

The patient-to-patient variability can be studied in Table 2. The lower standard deviation for relative $t_{\max}$ (second column) versus absolute $t_{\max}$ (first column) indicates that, once normalized individually, the variance in peak times decreases. The clearance of PPIX from the sensitized tissue appears to be even more sensitive to individual differences between the patients, resulting in a higher relative standard deviation of the clearance times (22%) compared to the absolute values of $t_{\max}$ (15%).

In order to be able to interpret the relative peak intensities $I_{\max}$ listed in the last column of Table 2, additional variations in the optical properties of the tissue have to be taken into account. Individual variations in the optical tissue parameters of each location can explain the high standard deviation of up to 25% of even the relative values.

For the routine clinical use of orally administered 5-ALA, a detailed knowledge of the induced transient photosensitization of the skin is quite important. Considering the good correlation between PPIX fluorescence and photosensitization of human skin [13], we observed that the highest risk for phototoxic reactions was about 8 h after 5-ALA application. In fact, the exposure to artificial light within this time range led to mild erythema in two of the patients. On the other hand, our investigations also indicate that with a slight individual uncertainty a significant photosensitization of normal skin does not persist longer than 40 h after administration.

In contrast to reports of Edwards [23] and Mustajoki [24], our own yet unpublished observations support the results of recently published studies [18,25] indicating that, besides the transient skin photosensitivity, an exogenous systemic 5-ALA loading might provoke other porphyric or even non-porphyrinic side-effects in morbid patients. Most of our patients tolerated an oral dosage of 40 mg kg^{-1} body weight quite well. Only a small group of partly high-risk patients showed mild complications from nausea to occasional vomiting and neurological symptoms, but also severe side-effects like hypotension in combination with a remarkable vasodilatation. The last complication in particular, which occurred between 2 and 8 h after application, seems to be inconsistent with the known hypertension in the case of acute hepatic porphyrias. Thus, a systemic administration of 5-ALA in excess might result in a clinical manifestation partly different to that observed with various kinds of porphyrias.

4.2. Pharmacokinetics of 5-ALA and PPIX in blood plasma

To provide a deeper insight into the distribution mechanisms of 5-ALA and PPIX in the organism and their possible

contribution to the observed side-effects, the second part of our study focused on the pharmacokinetics of both substances in blood plasma.

The examination of porphyrins in the circulation revealed a rapid rise of plasma porphyrin levels after oral application as well as after inhalation and intravesical instillation of 5-ALA. Only in the case of the least invasive application form using an ointment no porphyrins could be detected. However, only one patient had been evaluated. It can be stated that detectable amounts of PPIX might reach the plasma if large areas with reduced skin barrier are treated with ointment containing 5-ALA.

On comparing spectra from the plasma with those recorded from the series of standard solutions from uro- to protoporphyrin, we found no evidence for any porphyrin other than PPIX. In a solution containing predominantly PPIX, even small amounts of uro- or coproporphyrin resulted in a remarkable blue shift of the maximum, not observed in any of the investigated samples. Since the extraction procedure used was optimized for the highly lipophilic PPIX, we cannot strictly exclude the presence of a certain amount of the water-soluble uro- and coproporphyrins in the plasma. Further HPLC measurements will have to confirm the absence of significant concentrations of porphyrins other than PPIX. Nevertheless, we suppose that even in the case of an increased synthesis of uro- and coproporphyrin, their hydrophilic character should be responsible for the rapid clearance from the body. Therefore an accumulation comparable to that of PPIX should occur neither in the skin nor in the circulation.

The concentrations and peak times of PPIX determined in the plasma showed a strong dependence on the mode of application. Although all investigated routes of application led to a comparable fluorescence ratio between tumor and adjacent normal tissue, the mode of application played an important role for the systemic load of the patients with PPIX and 5-ALA.

Henderson et al. [7] studied the pharmacokinetics of PPIX in the circulation of tumor-bearing mice finding a peak concentration of more than $1200 \mu\text{g l}^{-1}$ PPIX 1 h after intraperitoneal injection of 1000 mg kg^{-1} body weight 5-ALA. After a single oral dose of 40 mg kg^{-1} body weight, we measured an average peak concentration of $742 \mu\text{g l}^{-1}$ PPIX in the plasma of patients, which is consistent with plasma levels of 2 to 4 mg l^{-1} detected by Webber et al. [26] in 4 patients 8 to 12 h after oral administration of 60 mg kg^{-1} body weight 5-ALA. Normal concentrations of PPIX in plasma measured in healthy volunteers have been reported to lie in the range of 0 to $8 \mu\text{g l}^{-1}$ [27].

In contrast to the at least 100-fold elevated plasma levels of PPIX after oral application, the mean maximum concentrations of $12 \mu\text{g l}^{-1}$ obtained for inhalation and even less for instillation and ointment are comparable to reference values [27]. Thus, side-effects due to PPIX for any of the topical routes of administration can be excluded.

A similar relationship has to be supposed for the plasma levels of 5-ALA after systemic ($\geq 32 \text{ mg l}^{-1}$) versus topical

($< 1 \text{ mg l}^{-1}$) application. A fast increase in circulating 5-ALA was noted for oral ingestion. This suggests that there is no efficient buffer for 5-ALA in the gastrointestinal tract. 5-ALA accumulation in the plasma reached a peak level of 32 mg l^{-1} already 30 min. after application. Since this value represents the first blood sample we took from the patients, we can not rule out an even higher concentration at earlier times.

In contrast to maximum concentrations of less than 0.1 mg l^{-1} of 5-ALA measured for topical application, the values for systemic application are utmost unphysiologic [28] and thus may contribute to the mentioned side-effects. The pathogenesis of the neurological dysfunctions in acute hepatic porphyrias and their correlation to circulating 5-ALA has not yet been clearly defined in literature. Nevertheless there is the hypothesis that the resemblance of 5-ALA to the neurotransmitter 4-aminobutyric acid is responsible for a neurotoxic potential of 5-ALA [4]. However, 5-ALA may form reactive oxygen species (ROS) by auto-oxidation leading to the neuropathological manifestations of acute hepatic porphyrias [29]. Assuming the fact that 5-ALA provokes the observed side-effects, a splitting of the administered dose over a longer period should result in reduced side-effects in combination with a comparable accumulation of PPIX. In patients with GI-tract cancer, Regula et al. were able to produce a plateau plasma concentration of about 8 mg l^{-1} 5-ALA by administration of a fractionated dosage of 30 mg kg^{-1} body weight, assuming that even higher doses of 5-ALA in the circulation might not induce porphyric symptoms [18]. When we compare the times at which side-effects occurred in our patients with the kinetics of 5-ALA and PPIX plasma levels (Fig. 5), a connection between side-effects and accumulating PPIX in the circulation seems to be more likely than a connection with circulating 5-ALA. Further investigations will have to give a more detailed insight into the correlation between systemic 5-ALA application and possible side-effects.

Although the biochemical steps of heme biosynthesis are largely understood [1,4], the distribution patterns of 5-ALA and PPIX in the organism after exogenous 5-ALA application are still discussed controversially [7,13]. On the one hand, the similar kinetics of PPIX in skin and plasma might support the theory of a centralized conversion of 5-ALA in erythroblasts or liver and a subsequent delivery to other organs via the circulation. However, the PPIX-fluorescence intensity contrast of tumor versus adjacent normal tissue is comparable after topical and systemic administration in contrast to the completely different plasma levels for both routes of application. This indicates that PPIX is more likely accumulated in epithelial cells by selective in situ synthesis from 5-ALA. In contrast to the usually protein-bound PPIX, hydrophilic 5-ALA may enter the interstitium easily from the blood vessels. Since every nucleated cell in the body must have at least a minimum capacity to synthesize PPIX from 5-ALA, an exclusive PPIX production in erythroblasts or liver is highly improbable.

We can not rule out that the bulk of circulating PPIX originates from the liver and may be responsible for a certain vascular photosensitivity [7]. Since injected PPIX and 5-ALA induced PPIX show a completely different tissue specificity [13], we nevertheless assume that the main part of PPIX in the tissue is synthesized in situ.

Acknowledgements

This study was supported by the Federal Ministry of Education and Research (BMBF), grant number 13N6311. The authors like to thank B. Hennel for technical assistance and J. Wessels for helpful discussions.

References

- [1] S.S. Bottomley, U. Müller-Eberhard, Pathophysiology of heme synthesis, *Semin. Hematol.*, 25 (1988) 282–302.
- [2] M.R. Moore, K.E.L. McColl, C. Rimington, A. Goldberg, Porphyrins and enzymes of the heme biosynthetic pathway, in: *Disorders of Porphyrin Metabolism*, Plenum, New York, pp. 21–116.
- [3] N.I. Berlin, A. Neuberger, J.J. Scott, The metabolism of δ -aminolaevulinic acid, *Biochem. J.*, 64 (1956) 80–100.
- [4] A.M. Battle, Porphyrins, porphyrias, cancer and photodynamic therapy – a model for carcinogenesis, *J. Photochem. Photobiol. B: Biol.*, 20 (1993) 5–22.
- [5] P. Heil, S. Stocker, R. Sroka, R. Baumgartner, In vivo fluorescence kinetics of porphyrins following intravesical instillation of 5-aminolaevulinic acid in normal and tumour bearing rat bladders, *J. Photochem. Photobiol. B: Biol.*, in press.
- [6] R. Sroka, W. Beyer, L. Gossner, T. Sassy, S. Stocker, R. Baumgartner, Pharmacokinetics of 5-aminolaevulinic-acid-induced porphyrins in tumour-bearing mice, *J. Photochem. Photobiol. B: Biol.*, 34 (1996) 13–19.
- [7] B.W. Henderson, L. Vaughan, D.A. Bellnier, H. Van Leengoed, P.G. Johnson, A.R. Oseroff, Photosensitization of murine tumor, vasculature and skin by 5-aminolaevulinic acid-induced porphyrin, *Photochem. Photobiol.*, 62 (1995) 780–789.
- [8] Z. Hua, S.L. Gibson, T.H. Foster, R. Hilf, Effectiveness of δ -aminolaevulinic acid-induced protoporphyrin as a photosensitizer for photodynamic therapy in vivo, *Cancer Res.*, 55 (1995) 1723–1731.
- [9] S. Iinuma, R. Bachor, T. Flotte, T. Hasan, Biodistribution and phototoxicity of 5-aminolaevulinic acid-induced PpIX in an orthotopic rat bladder tumor model, *J. Urol.*, 153 (1995) 802–806.
- [10] Z. Malik, G. Kostenich, L. Roitman, B. Ehrenberg, A. Orenstein, Topical application of 5-aminolaevulinic acid, DMSO and EDTA: protoporphyrin IX accumulation in skin and tumours of mice, *J. Photochem. Photobiol. B: Biol.*, 28 (1995) 213–218.
- [11] C.S. Loh, A.J. MacRobert, J. Bedwell, J. Regula, N. Krasner, S.G. Bown, Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy, *Br. J. Cancer*, 68 (1993) 41–51.
- [12] D.L. Campbell, E.F. Gudgin-Dickson, P.G. Forkert, R.H. Pottier, J.C. Kennedy, Detection of early stages of carcinogenesis in adenomas of murine lung by 5-aminolaevulinic acid-induced protoporphyrin IX fluorescence, *Photochem. Photobiol.*, 64 (1996) 676–682.
- [13] J.C. Kennedy, R.H. Pottier, Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy, *J. Photochem. Photobiol. B: Biol.*, 14 (1992) 275–292.
- [14] R. Baumgartner, R.M. Huber, H. Schulz, H. Stepp, K. Rick, F. Gamarra, A. Leberig, C. Roth, Inhalation of 5-aminolaevulinic acid: a new technique for fluorescence detection of early stage lung cancer, *J. Photochem. Photobiol. B: Biol.*, 36 (1996) 169–174.
- [15] L. Gossner, R. Sroka, E.G. Hahn, C. Ell, Photodynamic therapy: successful destruction of gastrointestinal cancer after oral administration of aminolaevulinic acid, *Gastrointest. Endosc.*, 41 (1995) 55–58.
- [16] M. Kriegmair, R. Baumgartner, R. Knuchel, H. Stepp, F. Hofstadter, A. Hofstetter, Detection of early bladder cancer by 5-aminolaevulinic acid induced porphyrin fluorescence, *J. Urol.*, 155 (1996) 105–109 (see comments).
- [17] A. Leunig, K. Rick, H. Stepp, R. Gutmann, A.E. Goetz, R. Baumgartner, J. Feyh, Fluorescence imaging and spectroscopy of 5-aminolaevulinic acid induced Protoporphyrin IX for the detection of neoplastic lesions in the oral cavity, *Am. J. Surg.*, in press.
- [18] J. Regula, A.J. MacRobert, A. Gorchein, G.A. Buonaccorsi, S.M. Thorpe, G.M. Spencer, A.R. Hatfield, S.G. Bown, Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX – a pilot study, *Gut*, 36 (1995) 67–75.
- [19] J.M. Wessels, R. Sroka, P. Heil, H.K. Seidlitz, Photodegradation of protoporphyrin-dimethylester in solution and in organized environments, *Int. J. Radiat. Biol.*, 64 (1993) 475–484.
- [20] K. Tomokuni, M. Ichiba, Y. Hirai, HPLC micro-method for determining δ -aminolaevulinic acid in plasma, *Clin. Chem.*, 39 (1993) 169–170.
- [21] Johannes Siebert, Personal communication, 1995.
- [22] D.W. Marquardt, An algorithm for least squares of estimation of nonlinear parameters, *J. Soc. Ind. Appl. Math.*, 11 (1963) 431–441.
- [23] S.R. Edwards, B.C. Shanley, J.A. Reynoldson, Neuropharmacology of δ -aminolaevulinic acid – I. Effect of acute administration in rodents, *Neuropharmacology*, 23 (1984) 477–481.
- [24] P. Mustajoki, K. Timonen, A. Gorchein, A.M. Seppäläinen, E. Matikainen, R. Tenhunen, Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer: no porphyric symptoms, *Eur. J. Clin. Invest.*, 22 (1992) 407–411.
- [25] D.M. Fiedler, P.M. Eckl, B. Krammer, Does δ -aminolaevulinic acid induce genotoxic effects? *J. Photochem. Photobiol. B: Biol.*, 33 (1996) 39–44.
- [26] J. Webber, D. Kessel, D. Fromm, Plasma levels of protoporphyrin IX in humans after oral administration of 5-aminolaevulinic acid, *J. Photochem. Photobiol. B: Biol.*, 37 (1997) 151–153.
- [27] M. Doss, Normal ranges of porphyrins and precursors in human tissue, urine and feces, in: J.J.T.W.A. Strik, J.H. Koeman (eds.), *Chemical porphyria in man*, Elsevier, North-Holland, Biomedical Press, Amsterdam, pp. 221–221.
- [28] A. Gorchein, R. Webber, δ -Aminolaevulinic acid in plasma, cerebrospinal fluid, saliva and erythrocytes: studies in normal, uraemic and porphyric subjects, *Clin. Sci.*, 72 (1987) 103–112.
- [29] M. Hermes-Lima, V.G. Valle, A.E. Vercesi, E.J. Bechara, Damage to rat liver mitochondria promoted by δ -aminolaevulinic acid-generated reactive oxygen species: connections with acute intermittent porphyria and lead-poisoning, *Biochim. Biophys. Acta*, 1056 (1991) 57–63.